Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection. This drug, along with bezlotoxumab...
3 KB (179 words) - 19:42, 19 October 2024
(including antibodies to Clostridioides difficile), antibodies now known as actoxumab and bezlotoxumab In 2005, the firm opened an $80 million facility for...
24 KB (2,243 words) - 05:24, 18 November 2024
lies within the N-terminus of the CROP domain. This drug, along with actoxumab, was developed through phase II efficacy trials by a partnership between...
12 KB (942 words) - 05:14, 20 October 2024
α4 β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease Actoxumab mab human Clostridioides difficile Clostridioides difficile colitis Adalimumab...
137 KB (4,083 words) - 21:25, 19 October 2024
Human Actoxumab§ Bezlotoxumab Suvratoxumab Chimeric Obiltoxaximab Humanized Urtoxazumab§...
24 KB (2,673 words) - 16:46, 2 November 2024